Itus Corp Cmn (ITUS) 3.26 $ITUS ITUS Corporation

New Post Public Reply Private Reply Replies (0) Message Board

Jun 22, 2016 at 9:09 PM

Itus Corp Cmn (ITUS) 3.26 $ITUS

ITUS Corporation (Nasdaq: ITUS) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Jun 02, 9:00AM CDT
What:
ITUS: 3.26 (-0.07), NDAQ: 63.09 (+0.12)

ITUS to Ring June 3, 2016 Nasdaq Closing Bell and Launch New Cancer Social Media Campaign
Marketwired - Tue May 31, 8:02AM CDT
LOS ANGELES, CA--(Marketwired - May 31, 2016) - ITUS Corporation (NASDAQ: ITUS) today announced that to commemorate National Cancer Survivor's Day on June 5, company representatives will ring the June 3, 2016 closing bell of The Nasdaq Stock Market. The occasion will also mark the official launch of a new cancer social media campaign entitled "Let's Get Crack'n Against Cancer."
ITUS: 3.26 (-0.07)

ITUS Featured on New York Radio Program
Marketwired - Thu Apr 28, 8:02AM CDT
ITUS Corporation ("ITUS"

(NASDAQ: ITUS) today announced that its President and CEO, Robert Berman, recently appeared on "Westchester On the Level with Narog and Aris," a news show broadcast by WHYT Radio. During the segment, Mr. Berman is interviewed by the show's host and Yonkers Tribune Editor, Hezi Aris.
ITUS: 3.26 (-0.07)

ITUS Featured on FOX News Health Segment
Marketwired - Mon Apr 25, 8:02AM CDT
ITUS Corporation ("ITUS"

(NASDAQ: ITUS), today announced that its President and CEO, Robert Berman, recently appeared on a health segment on cancer for FOX News. During the segment, Mr. Berman is interviewed by Fox News Channel's Senior Managing Editor for Health News, Dr. Manny Alveraz.
ITUS: 3.26 (-0.07)

ITUS Subsidiary Anixa Diagnostics Corporation Demonstrates Efficacy of Early Cancer Detection Platform With Lung Cancer
Marketwire Canada - Tue Apr 19, 8:00AM CDT
ITUS Corporation ("ITUS"

(NASDAQ: ITUS) today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has successfully demonstrated that its Ccheka"c early cancer detection platform can be used to identify the presence of lung cancer. The company will now expand its ongoing biomarker study to include additional lung cancer samples. Anixa previously announced results from the study with breast cancer patients.
ITUS: 3.26 (-0.07)

ITUS Featured on Several National and Local Radio Broadcasts
Marketwired - Thu Apr 14, 8:02AM CDT
ITUS Corporation ("ITUS"

(NASDAQ: ITUS) today announced that its President and CEO, Robert Berman, has recently appeared on several national and local radio broadcasts. Most recently, Mr. Berman appeared on NPR affiliate WFUV in New York. Last week, Mr. Berman was an hour-long guest on Joni Aldrich SOS, the iHeartRadio show hosted by nationally acclaimed cancer advocate Joni Aldrich.
ITUS: 3.26 (-0.07)

American Cancer Society Vice Chairman of the National Board of Directors, Dr. Arnold Baskies, Joins Scientific Advisory Board for ITUS Subsidiary Anixa Diagnostics Corporation
Marketwired - Mon Jan 25, 8:01AM CST
ITUS Corporation ("ITUS"

(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has added Dr. Arnold Baskies, the Vice Chairman of the Board of Directors of the American Cancer Society, to its Scientific Advisory Board. Dr. Baskies previously served as Chief Science Officer to the Board of Directors of the American Cancer Society and as President of the American Cancer Society of New York and New Jersey. He has been appointed by every New Jersey governor through 2015 to serve as Chair of the New Jersey Governor's Task Force on Cancer Prevention, Early Detection & Treatment.
ITUS: 3.26 (-0.07)

ITUS Subsidiary Anixa Diagnostics Corporation Appoints Dr. Michael Shepard to Its Scientific Advisory Board
Marketwired - Mon Dec 07, 8:01AM CST
ITUS Corporation ("ITUS"

(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has added Dr. Michael Shepard to its Scientific Advisory Board. Dr. Shepard is a pioneer in modern cancer research, whose many successes include work that lead to the discovery, development and launch of Herceptin, one of the best-selling cancer drugs of all time, used to treat breast cancer. Cumulative Herceptin sales have totaled more than $50 Billion, including sales in 2014 of greater than $7 Billion. Herceptin's approval opened the door for many other antibody therapies for cancer. For his work in this field, Dr. Shepard received the very prestigious Warren Alpert Prize, an annual award granted by The Warren Alpert Foundation, in association with Harvard Medical School, to scientists, physicians, and researchers, whose research constitutes a seminal scientific finding that holds great promise of ultimately changing our understanding of or ability to treat disease.
ITUS: 3.26 (-0.07)

ITUS Subsidiary Anixa Diagnostics Corporation Announces Initial Cancer Biomarker Results
Marketwired - Mon Oct 05, 8:02AM CDT
ITUS Corporation ("ITUS"

(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, in collaboration with The Wistar Institute, a National Cancer Institute-designated Cancer Center, has achieved very favorable initial results in a cancer biomarker study, successfully demonstrating the efficacy of Anixa's cancer screening technology. Wistar evaluated blood samples from a small group of patients with differing severities of breast cancer to determine the presence or absence of unique and anomalous biomarkers. Wistar also studied blood samples from a small group of healthy patients. The initial results showed the presence of the biomarkers in 100% of the cancer patients tested. Equally as important, none of the healthy patient blood samples contained the biomarkers.
ITUS: 3.26 (-0.07)

ITUS Subsidiary Auction Acceleration Corporation Enters Into Settlement and License Agreement With eBay, Vendio, & Auctiva
Marketwired - Wed Jul 15, 6:00AM CDT
ITUS Corporation ("ITUS"

(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Auction Acceleration Corporation ("AAC"

, has entered into a Settlement and License Agreement with eBay, Inc., Auctiva, LLC, and Vendio Services, LLC.
ITUS: 3.26 (-0.07), EBAY: 24.34 (-0.36)

ITUS Subsidiary Anixa Diagnostics Enters Into Collaborative Research Agreement With The Wistar Institute, a Leading Cancer Research Institute
Marketwired - Tue Jul 14, 11:52AM CDT
ITUS Corporation ("ITUS"

(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has entered into a Collaborative Research Agreement with The Wistar Institute, located on the campus of the University of Pennsylvania in Philadelphia, Pennsylvania, to further the development of a cancer screening test. Founded in 1892 as the nation's first independent biomedical research institute, Wistar is an international leader in the biomedical research fields of cancer, immunology and infectious diseases, a National Cancer Institute (NCI)-designated Cancer Center, and part of the NCI's select network of national cancer research centers, holding an 'Exceptional' rating -- the highest possible ranking awarded.
ITUS: 3.26 (-0.07)

ITUS Announces Uplisting to NASDAQ
Marketwired - Thu Jul 09, 3:01PM CDT
ITUS Corporation ("ITUS"

(OTCQB: ITUS) today announced that The NASDAQ Stock Market LLC has approved the listing of the Company's stock for trading on The NASDAQ Capital Market. Trading of the Company's securities on The NASDAQ Capital Market will commence effective with the opening of business on Friday, July 10, 2015.
ITUS: 3.26 (-0.07)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Goodal Skincare Capitalizes on K-Beauty Craze at Costco

A Venture into American Retail Goodal, the darling of Korea's skincare scene, is staking its claim at Costco. This is no small feat, my friends. We're talkin' about a brand that's carved out a sweet niche with its Green Tangerine line. Now it's hitching its wagon to one of America's retail behemoths, known for its unique knack in beauty products. From Olive Young to...

AMETEK Surpasses Q3 2026 Expectations, Raises Outlook

A Banner Quarter for AMETEK Holy smokes, AMETEK has thrown down some numbers for the third quarter of 2026 that would make any seasoned trader sit up and take notice. We’re talking record-breaking across the board: $2.22 billion in sales, marking a whopping 17% increase over last year. Now, that's not just growth—that's rocket fuel. Earnings per share rocketed up with...

Graphic Packaging's Q3 2026 Results: Mixed Signals

Graphic Packaging's Financial Figures: A Rough Ride Looking at the latest numbers from Graphic Packaging (NYSE: GPK), it's clear that the packaging landscape isn’t all wrapped up in a neat bow. Sure, the top line showed a slight uptick year-on-year with net sales nudging up $2 million to $2,192 million. Volumes were up too—by 1%—but that’s barely a blip when you...

PASCO scientific Appoints David Lopez as New CEO

New Leadership at PASCO scientific Here's the scoop: PASCO scientific is shaking things up at the top by welcoming David Lopez into the CEO chair as of October 5, 2026. Lopez comes packing over two decades of experience in education and organizational leadership. He's stepping into a legacy that's all about making science hands-on and exciting for students—not just in...

Mill Creek's Bold Move into Denver's Cherry Creek

Taking a Stroll Down Cherry Creek The move by Mill Creek Residential into Cherry Creek North is a bold one, but they aren't exactly newcomers to this high-end neighborhood. They're planting their flag with the Modera Second Avenue, targeting Denver's upscale renters. With a Walk Score of 89, the location is a sweet spot for deep-pocketed folks who want the boutiques and...

Memoir 'Pinball' Explores Life's Unpredictable Momentum

Funny how some folks think life has a road map. Let me tell you, it's more like a pinball machine, barely controllable and ready to surprise you with a tilt at any moment. And that's the essence of Marshall Barber's new memoir, 'PINBALL: Remembrances of a Flaneur.' Life's Roulette: Choices and Chance Barber takes readers on a raw ride through the byways of a life...

PRIMA Invests £10M to Propel CC Forum's Global Reach

Strategic Commitment for Global Impact You've got to hand it to these folks—they're on a mission to roll up their sleeves and tackle climate change head-on. Max Studennikoff, the brains behind CC Forum, just inked a Letter of Intent with Alexander Zhardanovsky, founder of PRIMA, punctuated by an eye-popping £10 million pledge. It's all about boosting the Forum’s...

Sesame Software's Game-Changer: Smooth CRM Switch

Why Leaving Salesforce Isn't as Crazy as It Sounds Stepping away from Salesforce isn't your run-of-the-mill decision for businesses. It’s more like abandoning ship, anticipating lurking dangers: losing cherished data, facing burdensome API restrictions, and fretting over years of trapped history. It’s not as simple as flipping a switch, and that’s what keeps most...

3M's Huge Settlement: Navigating A Looming Legal Fog

The latest chapter in 3M’s legal saga reads like a courtroom drama, but this time, the company's shelling out big bucks to sidestep prolonged courtroom battles. They're committing to a $5.8 billion payout over several years, aiming to put a lid on a massive batch of PFAS-related lawsuits. It’s like they’re cleaning the spill with a velvet mop, but the trick is...

Atomic Mobile's Global IoT Game Changer in Connectivity

Atomic Orbit Unlocks Global Connectivity Think about the hassle businesses face globally when devices drop off the grid. It's like losing a lifeline. Atomic Mobile, outta Spring Lake, decided enough's enough and dropped their latest brainchild on the world — Atomic Orbit. This bad boy is turning heads because it's not clinging to a single carrier. Instead, it's dancing...